Detection of SEZ6, a Therapeutic Target, in Medullary Thyroid Carcinoma
Authors' conclusion
SEZ6 may serve as a novel biomarker for MTCs. Although SEZ6 lacks any prognostic values in MTC, its positivity in 91% to 93% of MTCs, including MTCs without RET and RAS mutations, renders SEZ6-targeted antibody-drug conjugate therapy a promising targeted therapy for MTCs.
Study context
- Population
- Patients with medullary thyroid carcinoma (MTC); primary tumors, regional recurrence and distant metastasis
- Participants
- 78 MTCs
- Outcome
- SEZ6 immuno-expression in MTC
Main finding
As reported in the abstract
SEZ6 immunopositivity (antibody clones SC17.14 and 14E5)
Primary MTCs
91% to 93%
Regional recurrence
100%
Distant metastasis
75% to 83%
Further findings
Association of high SEZ6 immuno-expression (H score) with clinicopathologic features
- High SEZ6 associated with male sex, advanced stage and extrathyroidal extension
SEZ6 vs outcome and RET/RAS mutation status
- No correlation between SEZ6 expression and outcome or RET/RAS mutation status
SEZ6 positivity in MTC without RET/RAS mutations
- SEZ6 positivity frequency
- 83%
Original publication
Detection of SEZ6, a Therapeutic Target, in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. Published 26 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →